The filing is a routine investor presentation with no new material information. Monitor for FDA Division of Psychiatry meeting minutes expected June 2026, which could clarify the registrational path for zervimesine in DLB psychosis. The START Phase 2 Alzheimer's trial topline data in 2H 2027 is the next major catalyst.
Price Chart
Executive Summary
Cognition Therapeutics filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. The presentation highlights zervimesine (CT1816) for DLB psychosis, with Phase 2 SHIMMER data showing an 86% slowing of NPI-12 decline vs. placebo, and a planned registrational study following an FDA Division of Psychiatry meeting on May 20, 2026. No new financial data or guidance was provided; the filing is a routine regulatory disclosure of an existing corporate presentation.
Key Facts
- Investor presentation furnished under Item 7.01 Regulation FD for the Jefferies Global Healthcare Conference in June 2026.
- Lead asset zervimesine (CT1816) targets DLB psychosis, with no FDA-approved treatments currently available.
- Phase 2 SHIMMER study showed 86% slowing of NPI-12 decline vs. placebo in neuropsychiatric domains.
- FDA Division of Psychiatry meeting held May 20, 2026 to finalize registrational study design; minutes expected June 2026.
- Cash, equivalents & restricted cash of ~$31.2M as of March 31, 2026, with $25.6M in obligated NIA grant funds remaining.
- Cash runway into Q2 2027 based on current operating plan.
- Shares outstanding: 89.5M as of the presentation date.
- START Phase 2 trial in early Alzheimer's (545 patients, NIA-funded $81M) with topline data expected 2H 2027.
Financial Impact
No new financial data or guidance provided; cash position of ~$31.2M and runway into Q2 2027 reiterated from prior quarter.
Risk Factors
- Clinical-stage biotech with no approved products; regulatory and clinical trial risks remain high.
- Cash runway only into Q2 2027; likely need for additional financing before data readouts.
- DLB psychosis registrational program still in planning stages; FDA alignment not yet finalized.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-070345 |
| Document: tm2616896d1_8k.htm | 0001104659-26-070345 |
| Document: 0001104659-26-070345-index-headers.html | 0001104659-26-070345 |
| Document: 0001104659-26-070345-index.html | 0001104659-26-070345 |
| Document: 0001104659-26-070345.txt | 0001104659-26-070345 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7196 (+2.65%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7196 (−47.09%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7196 (−42.43%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7196 (−42.43%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7196 (−40.03%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7196 (−40.53%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7196 (−35.17%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7196 (−33.37%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7196 (−36.32%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7196 (−37.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers